23andMe as well as other spit-in-a-tube genetics companies have been profiting off of selling consumers’ genetic data to drugmakers, but recently, 23andMe took a more explicit step when they partnered with drug giant GlaxoSmithKline. 23andMe...
The genetic testing company 23andMe has sold its customers' data to GlaxoSmithKline for $500 million. Is this ethically justified? Darshan Kulkarni discusses some of the moral quandries behind selling genetic data, and whether customers are being...